ArticleFEBS open bio2017
Sirtuin 6 contributes to migration and invasion of osteosarcoma cells via the ERK1/2/MMP9 pathway.
Article in FEBS open bio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Retraction: microRNA526b servers as a prognostic factor and exhibits tumor suppressive property by targeting Sirtuin 7 in hepatocellular carcinoma.Oncotarget · 2026Article
- RETRACTION: Macrophage Deficiency Makes Intestinal Epithelial Cells Susceptible to NSAID-Induced Damage.BioMed research international · 2026Article
- Analysis of the Expression and Prognostic Value of SIRTs in Hepatocellular Carcinoma.International journal of general medicine · 2024Article
- The sirtuin family in health and disease.Signal transduction and targeted therapy · 2022Review
- SIRT2 promotes the viability, invasion and metastasis of osteosarcoma cells by inhibiting the degradation of Snail.Cell death & disease · 2022Article
- Review
- SIRT6 promotes mitochondrial fission and subsequent cellular invasion in ovarian cancer.FEBS open bio · 2022Article
- Inhibition of cell invasion and migration by targeting matrix metalloproteinase-9 expression via sirtuin 6 silencing in human breast cancer cells.Scientific reports · 2022Article
- Clinicopathological and prognostic value of SIRT6 in patients with solid tumors: a meta-analysis and TCGA data review.Cancer cell international · 2022Review
- ADP-Ribosylation as Post-Translational Modification of Proteins: Use of Inhibitors in Cancer Control.International journal of molecular sciences · 2021Review
- Emerging roles of SIRT6 in human diseases and its modulators.Medicinal research reviews · 2021Review
- The Multifaceted Therapeutic Mechanisms of Curcumin in Osteosarcoma: State-of-the-Art.Journal of oncology · 2021Review
- MMP-9 Knockdown Inhibits Oral Squamous Cell Carcinoma Lymph Node Metastasis in the Nude Mouse Tongue-Xenografted Model through the RhoC/Src Pathway.Analytical cellular pathology (Amsterdam) · 2021Article
- Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma.Journal of experimental & clinical cancer research : CR · 2020Article
- Increased DEF6 expression is correlated with metastasis and poor prognosis in human osteosarcoma.Oncology letters · 2020Article
- SIRT6 abrogation promotes adrenocortical carcinoma through activation of NF-κB signaling.Molecular and cellular biochemistry · 2019Article
- SIRT6/HIF-1α axis promotes papillary thyroid cancer progression by inducing epithelial-mesenchymal transition.Cancer cell international · 2019Article
- SIRT6 Is Involved in the Progression of Ovarian Carcinomas via β-Catenin-Mediated Epithelial to Mesenchymal Transition.Frontiers in oncology · 2018Article
- DGKZ Acts as a Potential Oncogene in Osteosarcoma Proliferation Through Its Possible Interaction With ERK1/2 and MYC Pathway.Frontiers in oncology · 2018Article
Corrections and comments
- Retraction · 2022-11-15Duplication of/in Image · Investigation by Third Party · Paper Mill · Unreliable Results and/or Conclusions · · see also: https://pubpeer.com/publications/3731D31823925E820EC7206135F049
- Retracted
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulation of sirtuin 6 (SIRT6) is actively involved in tumor progression. High levels of SIRT6 have been associated with hepatocellular carcinoma and non-small cell lung cancer, and SIRT6 facilitates growth and metastasis of cancer cells. However, the clinical significance and biological function of SIRT6 are not known for osteosarcoma (OS). Here, we report that SIRT6 was notably overexpressed in OS tissues compared with non-cancerous specimens. The high level of SIRT6 was prominently correlated with malignant clinical parameters and poor prognosis of OS patients. SIRT6 was also up-regulated in OS cells. SIRT6 knockdown inhibited the invasion and migration of Saos-2 and U2OS cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.